Aquestive Therapeutics, Inc. (AQST)
| Market Cap | 491.44M -27.8% |
| Revenue (ttm) | 48.84M +12.5% |
| Net Income | -79.28M |
| EPS | -0.64 |
| Shares Out | 125.69M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,966,973 |
| Open | 3.640 |
| Previous Close | 3.570 |
| Day's Range | 3.590 - 3.955 |
| 52-Week Range | 2.930 - 6.735 |
| Beta | 1.50 |
| Analysts | Strong Buy |
| Price Target | 9.33 (+138.7%) |
| Earnings Date | Nov 3, 2026 |
About AQST
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form o... [Read more]
Financial Performance
In 2025, Aquestive Therapeutics's revenue was $44.55 million, a decrease of -22.61% compared to the previous year's $57.56 million. Losses were -$83.78 million, 89.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for AQST stock is "Strong Buy." The 12-month stock price target is $9.33, which is an increase of 138.70% from the latest price.
News
Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improveme...
Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
WARREN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvem...
Aquestive Therapeutics Earnings Call Transcript: Q3 2026
Q3 revenue fell on lower Suboxone orders, while 9M revenue rose 14%. Anaphylm is under FDA review with a March 16, 2027 action date; year-end cash is expected above $70 million, and FY guidance was maintained.
Aquestive Therapeutics Earnings release: Q3 2026
Aquestive Therapeutics released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Aquestive Therapeutics Quarterly report: Q3 2026
Aquestive Therapeutics has published its Q3 2026 quarterly earnings report on November 4, 2026.
Aquestive Therapeutics Slides: Q3 2026
Aquestive Therapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Aquestive Therapeutics reports Q3 EPS (13c), consensus (14c)
Reports Q3 revenue $7.56M, consensus $11.02M. “With a PDUFA goal date of March 16, 2027, we believe we have a clear path to making Anaphylm available to patients and caregivers,…
Aquestive Therapeutics backs FY26 revenue view $46M-$50M, consensus $51.04M
Backs FY26 adjusted EBITDA loss view $30M-$35M. The company said, “Aquestive’s full-year 2026 financial guidance remains unchanged.”
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis,...
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvem...
Aquestive Therapeutics announces FDA acceptance of Anaphylm NDA resubmission
Aquestive Therapeutics (AQST) announced that the FDA has acknowledged its resubmission of the new drug application, or NDA, for Anaphylm sublingual film for the treatment of Type I allergic reactions,...
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvem...
Eton and Aquestive announce license and supply agreement for Libervant
Eton Pharmaceuticals (ETON) and Aquestive Therapeutics (AQST) announced that they have entered into an exclusive license agreement and a supply agreement covering the U.S. and its territories for LIBE...
Aquestive Therapeutics appoints Daly to board of directors
Aquestive Therapeutics (AQST) announced the appointment of Rich Daly to the Company’s Board of Directors, effective October 14, 2026. Following Mr. Daly’s appointment, the Board will consist of eight ...
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to it...
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026 FDA will determine the resubmission classification and establish the applicable...
Aquestive Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Anaphylm, an oral epinephrine film, is positioned for launch with strong clinical differentiation, robust commercial and financial readiness, and imminent FDA resubmission. The product targets significant unmet needs in an expanding market, with a disciplined strategy focused on key prescribers and patient access.
Aquestive Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Anaphylm, a sublingual film for severe allergic reactions, is poised for FDA resubmission with improved packaging and strong clinical data showing rapid onset and robust efficacy. The company is launch-ready with secured financing, a targeted commercial strategy, and a focus on payer engagement to highlight clinical and economic benefits.
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvemen...
Aquestive Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth and improved EBITDA loss, driven by higher manufacturing and royalty income. Anaphylm's NDA resubmission is on track, with positive human factors and PK data addressing FDA concerns. Cash position and new debt facility support launch readiness.
Aquestive Therapeutics Earnings release: Q2 2026
Aquestive Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Aquestive Therapeutics Quarterly report: Q2 2026
Aquestive Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Aquestive Therapeutics Slides: Q2 2026
Aquestive Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 12, 2026.
Aquestive Therapeutics reports Q2 EPS (18c), consensus (12c)
Reports Q2 revenue $13.82M, consensus $11.56M. “The epinephrine rescue market continues to grow and remains available for conversion from older medical device technology including autoinjectors,” said...
Aquestive Therapeutics backs FY26 revenue view $46M-$50M, consensus $50.51M
Backs FY26 adjusted EBITDA loss view $30M-$35M. “We also continue to expand our understanding of our AdrenaVerse epinephrine prodrug platform and the opportunity it presents,” continued Daniel Barber....